Evolent Health (NYSE: EVH) has recently received a number of price target changes and ratings updates: 8/18/2026 – Evolent Health was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”. 8/18/2026 – Evolent Health had its price target raised by JPMorgan Chase & Co. from $5.00 to $6.00. They now have an “overweight” rating […]

A number of research firms have changed their ratings and price targets for Phathom Pharmaceuticals (NASDAQ: PHAT): 7/31/2026 – Phathom Pharmaceuticals had its “buy” rating reaffirmed by Craig Hallum. They now have a $20.00 price target on the stock. 7/31/2026 – Phathom Pharmaceuticals had its price target lowered by Guggenheim from $25.00 to $22.00. They […]